News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Geza Acs

Articles by Geza Acs

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

ByCharlotta Wadsten,Karuna Mittal,Pat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balasubramanyam Karanam,Walter Bell,Charles E. Cox, MS, FACS,Abigail Beard,Geza Acs,Steven C. Shivers,David J. Dabbs,Jess Savala,Mark Mentrikoski,Troy Bremer

April 14th 2025

72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

ByTroy Bremer,Karuna Mittal,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balusubramanyam Karanam,Geza Acs,Elizabeth Pernicone,Melissa Tempest,Charles E. Cox, MS, FACS,Steven C. Shivers,Lotta Wadsten

April 13th 2024

Latest Updated Articles

Trending on CancerNetwork

How ADCs and BiTEs Are Propelling Change in Lung Cancer

Less Than Half of Incarcerated Population Receives Recommended Cancer Care

FDA Accepts NDA for Zidesamtinib in Pretreated Advanced ROS1+ NSCLC

Sequencing After Amivantamab + Lazertinib and Cumulative Toxicity

Managing Chemotherapy-Induced Toxicities in Stage II/III Lung Cancers

© 2025 MJH Life Sciences^®

All rights reserved.